Cargando…

An Approach to Derive Functional Peptide Inhibitors of Transcription Factor Activity

[Image: see text] We report the development of a high-throughput, intracellular “transcription block survival” (TBS) screening platform to derive functional transcription factor antagonists. TBS is demonstrated using the oncogenic transcriptional regulator cJun, with the development of antagonists t...

Descripción completa

Detalles Bibliográficos
Autores principales: Brennan, Andrew, Leech, James T., Kad, Neil M., Mason, Jody M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088798/
https://www.ncbi.nlm.nih.gov/pubmed/35557753
http://dx.doi.org/10.1021/jacsau.2c00105
_version_ 1784704386163802112
author Brennan, Andrew
Leech, James T.
Kad, Neil M.
Mason, Jody M.
author_facet Brennan, Andrew
Leech, James T.
Kad, Neil M.
Mason, Jody M.
author_sort Brennan, Andrew
collection PubMed
description [Image: see text] We report the development of a high-throughput, intracellular “transcription block survival” (TBS) screening platform to derive functional transcription factor antagonists. TBS is demonstrated using the oncogenic transcriptional regulator cJun, with the development of antagonists that bind cJun and prevent both dimerization and, more importantly, DNA binding remaining a primary challenge. In TBS, cognate TRE sites are introduced into the coding region of the essential gene, dihydrofolate reductase (DHFR). Introduction of cJun leads to TRE binding, preventing DHFR expression by directly blocking RNA polymerase gene transcription to abrogate cell proliferation. Peptide library screening identified a sequence that both binds cJun and antagonizes function by preventing DNA binding, as demonstrated by restored cell viability and subsequent in vitro hit validation. TBS is an entirely tag-free genotype-to-phenotype approach, selecting desirable attributes such as high solubility, target specificity, and low toxicity within a complex cellular environment. TBS facilitates rapid library screening to accelerate the identification of therapeutically valuable sequences.
format Online
Article
Text
id pubmed-9088798
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-90887982022-05-11 An Approach to Derive Functional Peptide Inhibitors of Transcription Factor Activity Brennan, Andrew Leech, James T. Kad, Neil M. Mason, Jody M. JACS Au [Image: see text] We report the development of a high-throughput, intracellular “transcription block survival” (TBS) screening platform to derive functional transcription factor antagonists. TBS is demonstrated using the oncogenic transcriptional regulator cJun, with the development of antagonists that bind cJun and prevent both dimerization and, more importantly, DNA binding remaining a primary challenge. In TBS, cognate TRE sites are introduced into the coding region of the essential gene, dihydrofolate reductase (DHFR). Introduction of cJun leads to TRE binding, preventing DHFR expression by directly blocking RNA polymerase gene transcription to abrogate cell proliferation. Peptide library screening identified a sequence that both binds cJun and antagonizes function by preventing DNA binding, as demonstrated by restored cell viability and subsequent in vitro hit validation. TBS is an entirely tag-free genotype-to-phenotype approach, selecting desirable attributes such as high solubility, target specificity, and low toxicity within a complex cellular environment. TBS facilitates rapid library screening to accelerate the identification of therapeutically valuable sequences. American Chemical Society 2022-04-06 /pmc/articles/PMC9088798/ /pubmed/35557753 http://dx.doi.org/10.1021/jacsau.2c00105 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brennan, Andrew
Leech, James T.
Kad, Neil M.
Mason, Jody M.
An Approach to Derive Functional Peptide Inhibitors of Transcription Factor Activity
title An Approach to Derive Functional Peptide Inhibitors of Transcription Factor Activity
title_full An Approach to Derive Functional Peptide Inhibitors of Transcription Factor Activity
title_fullStr An Approach to Derive Functional Peptide Inhibitors of Transcription Factor Activity
title_full_unstemmed An Approach to Derive Functional Peptide Inhibitors of Transcription Factor Activity
title_short An Approach to Derive Functional Peptide Inhibitors of Transcription Factor Activity
title_sort approach to derive functional peptide inhibitors of transcription factor activity
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088798/
https://www.ncbi.nlm.nih.gov/pubmed/35557753
http://dx.doi.org/10.1021/jacsau.2c00105
work_keys_str_mv AT brennanandrew anapproachtoderivefunctionalpeptideinhibitorsoftranscriptionfactoractivity
AT leechjamest anapproachtoderivefunctionalpeptideinhibitorsoftranscriptionfactoractivity
AT kadneilm anapproachtoderivefunctionalpeptideinhibitorsoftranscriptionfactoractivity
AT masonjodym anapproachtoderivefunctionalpeptideinhibitorsoftranscriptionfactoractivity
AT brennanandrew approachtoderivefunctionalpeptideinhibitorsoftranscriptionfactoractivity
AT leechjamest approachtoderivefunctionalpeptideinhibitorsoftranscriptionfactoractivity
AT kadneilm approachtoderivefunctionalpeptideinhibitorsoftranscriptionfactoractivity
AT masonjodym approachtoderivefunctionalpeptideinhibitorsoftranscriptionfactoractivity